---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-001076"
form_type: "8-K"
ticker: null
cik: "0000879682"
company_name: "VIVEVE MEDICAL, INC."
filed_at: "2023-01-17T23:59:59+00:00"
generated_at: "2026-06-20T15:06:29.644193+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Viveve PURSUIT SUI trial fails primary endpoint; company to delist, reduce workforce, explore sale or wind-down

## Summary
- PURSUIT trial did not meet primary endpoint: 49.8% active vs 56.7% sham responders (p=0.2035) on 1-hour pad weight test at 12 months.
- Company reducing workforce, exploring strategic alternatives including sale or wind-down of operations.
- Nasdaq will delist stock after Jan 19 hearing; company plans to file Form 15 to suspend SEC reporting.
- No serious device-related adverse events reported.

## SEC filing metadata
- accession: 0001437749-23-001076
- form_type: 8-K
- cik: 0000879682
- company_name: VIVEVE MEDICAL, INC.
- filed_at: 2023-01-17T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.05, 3.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879682/000143774923001076/0001437749-23-001076-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879682/000143774923001076/vive20230116_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-001076
- JSON: https://secwatch.observer/filing/0001437749-23-001076.json
- Plain text: https://secwatch.observer/filing/0001437749-23-001076.txt

## Key facts
- Listing & Compliance Notices
  VIVEVE MEDICAL, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5550(b)(1)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2), 5550(b)(1)
  source text: November 29, 2022, the Company received notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the Company’s non-compliance with the minimum bid price and stockholders’ equity requirements for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rules 5550(a)(2) (the “Bid Price Rule”) and 5550(b)(1) (the “Equity Rule”), respectively, the Company’s securities were subject to delisting unless the Company timely requested a hearing before the Nasdaq Hearings Panel (the “Panel”). On December 5, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/879682/000143774923001076/0001437749-23-001076-index.htm
- Restructurings & Charges
  VIVEVE MEDICAL, INC. announced a restructuring with charges of approximately $25,000.
  - Type: restructuring
  - Charge: approximately $25,000
  source text: On January 14, 2023, the Board of Directors (the “Board”) of Viveve Medical, Inc. (the “Company”) approved a reduction of the Company’s workforce. The Company expects to record a charge of approximately $25,000 in the first quarter of 2023 relating to the reduction in force, which is expected to consist of healthcare and benefits related costs and expenses.
  evidence_url: https://www.sec.gov/Archives/edgar/data/879682/000143774923001076/0001437749-23-001076-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.